影响因子(Impact Factor)是衡量学术期刊影响力的指标,它反映了一定期限内发表在该期刊上的科学论文的被引用次数。影响因子的计算根据某一特定年份的引文数,将这些引文分为正文引文和期刊自身引文两部分,再将正文引文数除以该期刊前两年内发表的论文总数,就得到了该期刊的影响因子。 那么,神经肿瘤学实践的影响因子具体有...
5-year Journal Impact Factor 3.7 (2023) Submission to first decision (median) 1 days Downloads 943,749 (2023) Call for papers Collection Innovation and Emerging Treatment Strategies for High Grade Gliomas In this special collection of the Journal of Neuro-Oncology, we provide a comprehensive over...
On average, self citation was responsible for 16.2 卤 1.3% (mean 卤 SE) of the impact factor in 2004. The self-citation rates decrease with ... JOCHEN KRAUSS - 《Scientometrics》 被引量: 54发表: 2007年 Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma ...
汤森路透每年出版一本《期刊引用报告》(Journal Citation Reports,简称JCR)。JCR对86000多种SCI期刊的影响因子(Impact Factor)等指数加以统计。JCR将收录期刊分为176个不同学科类别在JCR的Journal Ranking中,主要参考当年IF,最终每个分区的期刊数量是均分的。
JCR 影响因子(Impact factor), 5年期影响因子, 即年指数(Immediacy Index), 论文数量, 半衰期, 特征因子(Eigenfactor), 论文影响分值 [科研必备] 专业SCI论文修改服务: ★先修改后付款;☆语言问题免费重修;★24-72小时交稿; ☆正规财务发票;★一分钟下单;☆365日不间断服务 期刊全名 neuro-oncology 期刊简称 NE...
Journal Impact Factor: 0.36 Average acceptance to publication time (5-7 days) Average article processing time (30-45 days)Less than 5 volumes 30 days 8 - 9 volumes 40 days 10 and more volumes 45 days Editorial Panel Alireza Heidari, , Ph.D., D.Sc. ...
documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) ...
尽管表皮生长因子受体(epidermal growth factor receptor, egfr)及egfrviii突变被认为是部分胶质瘤的驱动基因,但是既往临床研究发现,即使在瘤内达到有效药物浓度,针对egfr的络氨酸激酶抑制剂均未取得较好的结果.而针对egfr的中和抗体研究也并未改善胶质瘤患者的生存期.因此,sameer等利用患者来源的表达内源性egfrviii的胶质...
Most importantly, he has increased the quality and importance of the publications, raising its impact factor in 2012 to 6.18, making it the highest-ranking journal in the field of neuro-oncology, 10th of 192 clinical neurology journals, and 24th of 196 oncology journals. We are very grateful ...
尽管表皮生长因子受体(epidermal growth factor receptor, EGFR)及EGFRvIII突变被认为是部分胶质瘤的驱动基因,但是既往临床研究发现,即使在瘤内达到有效药物浓度,针对EGFR的络氨酸激酶抑制剂均未取得较好的结果。而针对EGFR的中和抗体研究也并未改善胶质瘤患者的生存期。因此,Sameer等利用患者来源的表达内源性EGFRvIII的胶质...